R Danny Huntington began his career as a chemist at the Gillette Research Institute. Shortly after joining the institute, he became the patent liaison to outside patent counsel and later to in-house attorneys at parent company, The Gillette Company. Finding the interface between technology and patent law fascinating, after earning his law degree he joined the patent staff of The Gillette Company, where he continued to represent the institute.
After entering private practice in Boston, he wrote and prosecuted some of the earliest-filed biotechnology patent applications. He was also involved in district court litigation and patent interferences, the latter primarily in the field of pharmaceuticals.
In 1981 he moved to the Washington DC area and continued a varied practice until the US Patent and Trademark Office started declaring patent interferences involving biotechnology. Mr Huntington was one of the few attorneys knowledgeable in both interferences and biotechnology, and he soon found himself spending most of his time working in this field. His expertise in biotechnology interferences led him to handle interferences involving other technologies. He has now handled more than 200 interferences and he frequently lectures on interference practice.
In addition to traditional uses of interferences, Mr Huntington has promoted interferences as an alternative vehicle for defending against non-practising entities, sometimes referred to as ‘patent trolls’. This type of practice has transitioned readily into the new inter partes review and post-grant review, since these are essentially the same as the first stage of an interference, with the possible addition of some discovery.
His practice continues to include all phases of IP law, including US and foreign patent prosecution, litigation in the federal courts, licensing and general client counselling. Having practised both in-house and in private practice, he can provide advice that takes into account the various issues confronting rights holders.
Mr Huntington is also ranked in the IAM Strategy 300.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email